Last update 19 Sep 2024

Bupropion Hydrochloride

Last update 19 Sep 2024

Overview

R&D Status

Clinical Result

Translational Medicine

Overview

Basic Info

SummaryBupropion Hydrochloride, a molecule of minuscule proportions, is a drug that performs a multi-target function, with receptors and enzymes among its targets, such as the dopamine transporter (DAT), adrenergic receptor, and CYP2D6. Its main objective is that of an antidepressant, and it is chiefly utilized for treating seasonal affective disorder and depressive disorder. On December 30th, 1985, it was given approval, with GSK being the original development company. Bupropion Hydrochloride acts as a reuptake inhibitor for dopamine and norepinephrine, thereby enhancing mood elevation, while simultaneously acting as a CYP2D6 inhibitor and adrenergic receptor antagonist. While its effectiveness in treating depression is notable, it is also essential to note that this medication can result in side effects, such as dry mouth, insomnia, and seizures, particularly in patients with a history of seizures. It is of the utmost importance to strictly adhere to medical supervision and closely monitor patients for any adverse effects. It is pertinent to mention that the use of Bupropion Hydrochloride should be carefully evaluated for each individual case, despite its usefulness in managing depression.

Drug Type

Small molecule drug

Synonyms

Amfebutamone Hydrochloride, Bupropion, Bupropion Hrdrochloride

+ [22]

Target

CYP2D6 x DAT x NET x adrenergic receptor

Mechanism

CYP2D6 inhibitors(Cytochrome P450 2D6 inhibitors), Dopamine reuptake inhibitors, Norepinephrine reuptake inhibitors

+ [1]

Therapeutic Areas

Other DiseasesNeoplasms

Active Indication

Seasonal Affective DisorderDepressive Disorder, MajorDepressive Disorder+ [2]

Inactive Indication

Attention Deficit DisorderCrohn DiseaseDepression+ [6]

Originator Organization

GSK Plc

Active Organization

Research Triangle InstituteBausch Health US LLC

GSK Plc

+ [3]

Inactive Organization

GlaxoSmithKline (China) Investment Co., Ltd.Glaxo Wellcome GmbH & Co. KGBiovail Corp.

Drug Highest PhaseApproved

First Approval Date

US (30 Dec 1985),

Depressive Disorder, Major

RegulationPriority Review (CN)

Structure

Molecular FormulaC13H19Cl2NO

InChIKeyHEYVINCGKDONRU-UHFFFAOYSA-N

CAS Registry31677-93-7

View All Structures (2)

319

Clinical Trials associated with Bupropion Hydrochloride

IRCT20190325043107N48 / SuspendedPhase 2/3IIT

Investigating the effect and side effects of bupropion on fatigue, disability and quality of life of multiple sclerosis patients

Start Date21 Oct 2024

Sponsor / Collaborator

Tabriz University of Medical Sciences

ChiCTR2400088590 / SuspendedNot ApplicableIIT

A study on the efficacy and safety of bupropion for the improvement of symptoms during the acute phase and maintenance phase of depressive episodes in adults with bipolar affective disorder.

Start Date01 Oct 2024

Sponsor / Collaborator-

NCT06564441 / Not yet recruitingPhase 1

An Open-label, Non-randomised, Fixed-sequence, Two Period, Phase I Trial to Evaluate the Effect of Different Doses of BI 456906 (Survodutide) on the Single Dose Pharmacokinetics of Bupropion, Caffeine and Midazolam on Otherwise Healthy Volunteers With Overweight or Obesity

This study is open to adults with overweight or obesity who are otherwise healthy. People can join the study if they have a body mass index of 27 to 39.9 kg/m2 and a body weight over 70 kg. The purpose of this study is to find out whether taking multiple doses of BI 456906 influences the amount of bupropion, caffeine, and midazolam in the blood.
The study has 2 treatment periods. In Period 1, participants take 1 dose each of midazolam, caffeine, and bupropion as tablets or oral solution on separate days. In Period 2, participants get BI 456906 as an injection under the skin once a week. At 2 selected timepoints in Period 2, participants also take midazolam, caffeine and bupropion as tablets or oral solution on separate days.
Participants are in the study for about 13 months. They visit the study site up to 45 times. At 3 of those visits, participants stay for 5 or 6 days at the study site. During the visits, doctors collect information about participants' health and take blood samples from the participants. They compare the amounts of midazolam, caffeine, and bupropion in the blood in Period 2 with the amounts in Period 1. Doctors also regularly check participants' health and take note of any unwanted effects.

Start Date05 Sep 2024

Sponsor / Collaborator

Boehringer Ingelheim GmbH

100 Clinical Results associated with Bupropion Hydrochloride

100 Translational Medicine associated with Bupropion Hydrochloride

100 Patents (Medical) associated with Bupropion Hydrochloride

349

Literatures (Medical) associated with Bupropion Hydrochloride

31 Dec 2024·Journal of Medical Economics

Real-world treatment patterns of patients with major depressive disorder treated with Auvelity in the United States

Article

Author: Zhao, Yang ; Syed, Fatima Zahara ; Cong, Junjun ; Zhou, Huanxue ; Tabuteau, Herriot ; Muzyk, Andrew

AIMSMajor depressive disorder (MDD) is a prevalent, chronic disorder. Auvelity (dextromethorphan-bupropion) is a novel, oral N-methyl-D-aspartate (NMDA) receptor antagonist and sigma-1 receptor agonist approved (August 2022) by the FDA for treating MDD in adults. This is the first analysis on real-world Auvelity usage in the United States.METHODSAdult patients initiating Auvelity in the Symphony IDV databases by September 2023 were identified (index date: the first Auvelity claim). Patients had continuous eligibility over the 12-month pre-index period and ≥1 MDD diagnosis (ICD-10-CM codes: F32.*, F33.*) over the 5-year pre-index period. Demographic and clinical characteristics, comorbidities, prior MDD-related medications, and Auvelity initiation status were assessed.RESULTSThis analysis included 22,288 patients with MDD treated with Auvelity (mean age 45.1 years; 68.1% women); 40.0% lived in the South and 58.5% had commercial insurance. Comorbidities included mental health disorders (53.5%; 47.6% had anxiety disorders). Overall, 83.7% of the patients had received treatment with selective serotonin reuptake inhibitors (SSRIs; 54.9%), the norepinephrine-dopamine reuptake inhibitor (NDRI [bupropion]; 40.4%), and/or serotonin-norepinephrine reuptake inhibitors (SNRIs; 35.9%) over the 12-month pre-index period. The last MDD-related treatment prior to Auvelity comprised SSRI (22.4%), SNRI (13.2%), and NDRI (12.8%) monotherapies; 294 (1.3%) patients received esketamine. In total, 6,418 (28.8%) patients initiated Auvelity as monotherapy vs 15,870 (71.2%) as an add-on; Auvelity was most frequently added to an SSRI alone (10.7%) or SNRI alone (6.5%). A total of 2,254 (10.1%) patients initiated Auvelity without prior treatment in the 12-month pre-index period.LIMITATIONSIncomplete data due to reporting; diagnoses captured subject to coding error; and limited generalizability to other populations.CONCLUSIONSUsing a large demographically distributed claims database, 22,288 patients with MDD initiated Auvelity within a year of its approval; 10.1% were treatment-naïve and 28.8% initiated Auvelity as monotherapy. Most patients had mental health-related comorbidities and attempted various MDD-related treatments prior to Auvelity.

01 Dec 2024·Atención Primaria

Prescripción de fármacos para la deshabituación tabáquica. Análisis retrospectivo del área de salud de Zamora

Article

Author: Amaro Rodríguez, Laura ; Ruiz Cimarras, Manuel Angel ; Fernández-Martínez, Maria Nélida ; Espinosa Villoria, Maria Guadalupe ; Majo García, Raúl ; Fernández-García, Daniel

OBJECTIVETo analyze the prescription of drugs to aid smoking cessation and to detect whether there are differences by age or sex.DESIGNRetrospective cohort study. SITE: Zamora Health Area.PARTICIPANTSPersons with smoking cessation attempts employing drugs funded in the period from 2020 to 2023.INTERVENTIONSRequest of pharmaceutical consumption of varenicline, bupropion and cytisine to the Pharmacy Information System of the Regional Health Management of Castilla y León.MAIN MEASUREMENTSNumber of quit attempts per person, treatment drug, number of medication containers per attempt, year, age and sex. Descriptive and statistical analysis using SPSS© v. 20.RESULTS2581 people tried to quit smoking with drugs, 2206 made one attempt and 375 made several attempts. Mean age was 50.7 years (95% CI: 50.2-51.1). No significant differences were found for age (P=.71) or sex (P=.74). There was a preference for prescribing varenicline over bupropion and low drug compliance, with only one container of medication being collected in about 50% of cases. A total of 1680 attempts were made to quit using cytisine in 2023, equivalent to 55.4% of the total number of treatment drugs used in the four years. The estimated cumulative incidence rate of drug withdrawal attempts in smokers between 18 and 65 years of age was 11.9%.CONCLUSIONSThe drug intervention had a low reach and poor compliance with the recommended treatment. It is essential to emphasize patient follow-up and drug adherence.

01 Nov 2024·Addictive Behaviors

Choice of smoking cessation products among people with substance use problems in the US: Findings from the Population Assessment of Tobacco and Health (PATH) study Wave 6

Article

Author: Koning, Stephanie ; Erinoso, Olufemi ; Wagner, Karla D ; Lu, Minggen ; Pearson, Jennifer ; Watts, Theresa

OBJECTIVEThe aim of this study was to compare past 12-month use of cigarette smoking cessation aids (e.g., Food and Drug Administration (FDA)-approved cessation products or e-cigarettes for smoking cessation) among people with substance use problems (PWSUPs) who currently smoke to people without substance use problems (SUPs) who currently smoke cigarettes in a nationally representative US sample.METHODSWe used the Population Assessment of Tobacco and Health (PATH) Wave 6 Study [n = 30,516]. Our sample comprised adult (18+) established cigarette smokers (100+ lifetime-sticks with daily/non-daily use) [n = 5,895]. The independent variable was SUP status (no, moderate, and high). The dependent variables were past-year use of: nicotine replacement therapies (NRTs), cessation medications [i.e., varenicline or bupropion], or e-cigarettes [for cigarette cessation and reduction]. Weighted multivariable logistic regression models for each dependent variable examined the associations between SUP status and each cessation aid, adjusting for cigarette dependence, daily cigarette smoking, and demographic factors.RESULTSAmong people who smoke, a higher proportion of respondents with high SUP severity used NRTs, cessation medications, and e-cigarettes for cigarette cessation, respectively (12.3%, 8.4%, 15.7%), compared to those with no/low SUP severity (9.8%, 6.0%, 8.9%). In the multivariable models, respondents with high SUPs had 63% (95% CI:1.16-2.29) higher odds of using e-cigarettes for cessation than those without SUPs. No significant differences were seen between high (vs. no/low SUPs) in the past-year use of NRTs and cessation medications.CONCLUSIONOur findings indicate that cigarette smokers with high SUPs had higher odds of using e-cigarettes for cessation and reduction compared to smokers without SUPs.

News (Medical) associated with Bupropion Hydrochloride

15 Aug 2024

·www.globenewswire.com

BioCorRx Reports Business Update for the Second Quarter of 2024

ANAHEIM, CA, Aug. 15, 2024 (GLOBE NEWSWIRE) -- BioCorRx Inc. (OTCQB: BICX) (the “Company”), a developer and provider of innovative treatment programs for substance abuse and related disorders, today provided a business update for the three months ended June 30, 2024, and reported on recent corporate developments. Additionally, BioCorRx Inc. announces the expansion of its intellectual property portfolio with a new international patent awarded from Israel for the treatment of weight loss. This patent covers the use of a subcutaneous implant containing naltrexone to aid in weight loss when combined with behavioral and/or nutritional counseling and therapy. This patent aligns with BioCorRx’s long-term goals of addressing the global unmet medical needs related to obesity and strengthens the Company’s IP portfolio. Lourdes Felix, CEO, CFO, and Director of BioCorRx Inc., commented, “In the second quarter of 2024, we announced that our subsidiary, BioCorRx Pharmaceuticals Inc., was granted a new patent by the United States Patent and Trademark Office (USPTO) for a novel compound. We believe this patented invention could offer a new approach to reducing the severity of withdrawal symptoms for opioid use disorder (OUD) compared to current treatments. Recently, we were granted a new patent from Israel for the use of a subcutaneous naltrexone implant to aid weight loss when combined with behavioral or nutritional counseling. This further expands our IP portfolio and supports our goals in addressing global obesity.” “Additionally in February 2024, BioCorRx Pharmaceuticals received a 3-year grant totaling approximately $11 million from the National Institute on Drug Abuse (NIDA), a division of the National Institutes of Health (NIH). This grant is designated for the development of BICX104, a subcutaneous, long-duration naltrexone implantable pellet intended for the treatment of methamphetamine use disorder (MUD), either as a standalone therapy or in combination with bupropion. MUD is a significant public health challenge, affecting individuals, families, and communities across the nation. With no approved medications currently available specifically for MUD, and an expanding demographic at risk of methamphetamine-related overdose deaths, this funding will greatly accelerate our research efforts to develop BICX104 as a potential treatment. We remain optimistic about our business and are excited about the ongoing progress in our development. Our focus continues to be on executing our strategic priorities to create significant value for shareholders, and we look forward to sharing additional operational and regulatory updates soon,” concluded Ms. Felix. A copy of the Company’s quarterly report on Form 10-Q for the second quarter ended June 30, 2024, has been filed with the Securities and Exchange Commission and posted on the Company’s website at https://ir.biocorrx.com/. About BICX104 BICX104 is a biodegradable, long-acting subcutaneous pellet of naltrexone for the treatment of Opioid Use Disorder “OUD” being developed with the goal of improving patient compliance to naltrexone therapy compared to other marketed treatments. In Phase I, an open-label, single-center study in two parallel groups of randomized healthy volunteers to evaluate the PK and safety of BICX104 and the once-a-month intramuscular naltrexone injection (Vivitrol), BICX104 was well tolerated with no serious adverse events and achieved 84 days of therapeutic naltrexone plasma concentrations. BICX104 is being developed under BioCorRx Pharmaceuticals Inc., the Company’s majority-owned clinical-stage pharmaceutical subsidiary. Information about the study can also be found at www.clinicaltrials.gov under NCT number 04828694. BICX104 is being developed through a cooperative agreement with the NIDA, part of the NIH, under award number UH3DA047925, funded by the Helping to End Addiction Long-term Initiative, or NIH HEAL Initiative. This award is subject to the Cooperative Agreement Terms and Conditions of Award as set forth in RFA DA-19-002 entitled, Development of Medications to Prevent and Treat Opioid Use Disorders and Overdose (UG3/UH3) (Clinical Trial Optional). The NIH Helping to End Addiction Long-term® Initiative or NIH HEAL Initiative®, is an aggressive, trans-NIH effort to speed scientific solutions to stem the national opioid public health crisis. Launched in April 2018, the initiative is focused on improving prevention and treatment strategies for opioid misuse and addiction and enhancing pain management. For more information, visit: https://heal.nih.gov. Research reported in this publication was supported by the National Institute On Drug Abuse of the National Institutes of Health under Award Number U01DA059994 and UH3DA047925. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health. About MUD Research has shown that methamphetamine is a highly addictive stimulant and one of the most misused stimulant drugs in the world. Some of the side effects of MUD are severe dental problems, memory loss, aggression, psychotic behavior, and damage to the cardiovascular system. In 2022 the National Survey on Drug Use and Health reported that more than 16.6 million people used methamphetamine at least once during their lifetime. About OUD OUD is a chronic disorder, with serious potential consequences including disability, relapses, and death. Opioids, used medically for pain relief, have analgesic and central nervous system depressant effects as well as the potential to cause euphoria with an overpowering desire to use opioids despite the consequences. OUD can involve misuse of prescribed opioid medications, use of diverted opioid medications or illicitly obtained heroin. OUD is typically a chronic and relapsing illness that is associated with significantly increased rates of morbidity and mortality. About Obesity It is estimated that 1 billion people worldwide are obese. In 2024 the World Health Organization reported that one in eight people live with obesity and stressed the importance and need to curb the obesity epidemic with new interventions. It is estimated that by 2035 the global obesity crisis could rise to over 4 billion people. Affecting healthcare costs upwards of $4 trillion with obesity-related conditions including; stroke, heart disease, cancer, and type 2 diabetes. About BioCorRx Inc. BioCorRx Inc. (OTCQB: BICX) is an addiction treatment solutions company offering a unique approach to the treatment of substance use and other related disorders. Beat Addiction Recovery is a substance use disorder recovery program that typically includes BioCorRx's proprietary Cognitive Behavioral Therapy (CBT) modules along with peer support via mobile app along with medication prescribed by an independent treating physician under their discretion. The UnCraveRx® Weight Loss Program is also a medication-assisted weight loss program that includes access to concierge on-demand wellness specialists: nutritionists, fitness experts, and personal support from behavioral experts, please visit www.uncraverx.com for more information on UnCraveRx®. The Company also controls BioCorRx Pharmaceuticals Inc., a clinical-stage drug development subsidiary currently seeking FDA approval for BICX104, an implantable naltrexone pellet for the treatment of alcohol and opioid use disorders. For more information on BICX and its subsidiary pipeline, please visit www.BioCorRx.com. Forward-Looking Statements This press release contains forward-looking statements. These forward-looking statements generally are identified by the words "believe," "project," "estimate," "become," "plan," "will," and similar expressions. These forward-looking statements involve known and unknown. risks as well as uncertainties. Although the Company believes that its expectations are based on reasonable assumptions, the actual results that the Company may achieve may differ materially from any forward-looking statements, which reflect the opinions of the management of the Company only as of the date hereof. BioCorRx Inc. investors@BioCorRx.com714-462-4880 Investor Relations:Crescendo Communications, LLC212- 671-1020 x304bicx@crescendo-ir.com

Phase 1Clinical Result

10 Jun 2024

·www.drugs.com

Two-Drug Treatment Could Curb Meth Addiction

MONDAY, June 10, 2024 — Though overdose deaths continue to surge, there is no approved medication to treat methamphetamine use disorder. Now, an experimental two-drug therapy has yielded promising results, UCLA researchers report. "These findings have important implications for pharmacological treatment for methamphetamine use disorder," said researcher Dr. Michael Li , an assistant professor-in-residence of family medicine at the David Geffen School of Medicine at UCLA, adding that methamphetamine-involved overdoses have surged. His team published its findings June 10 in the journal Addiction . In urine tests for methamphetamine, drug-free results rose 27% among participants who received a combination of injectable naltrexone plus extended-release oral buproprion. Negative tests rose only 11%, meanwhile, in a control group. Methamphetamine abuse is a growing problem around the world, with an estimated 34 million users in 2020 compared to 33 million 10 years earlier. In the United States alone, overdose deaths rose fivefold between 2012 and 2018. The National Institute on Drug Abuse Clinical Trials Network has supported various trials, including this one, to evaluate different treatments for methamphetamine use disorder. This trial, known as ADAPT-2, ran from May 2017 to July 2019 at eight sites. More than 400 participants were included, including 109 who received the experimental drug therapy in the first phase. That demonstrated that the combo worked at six weeks. The new findings are from the trial's second phase, which looked at a longer period. Partipants were drug-tested at weeks seven and 12 and again, after treatment, at 13 and 16 weeks. While their results were encouraging, researchers said further study is needed to find out if the treatment lasts longer than 12 weeks and leads to further reductions in drug use. "Prior stimulant use disorder treatment trials suggest that change in use is gradual [consistent with our findings], unlikely to result in sustained abstinence in a typical 12-week trial, and dependent on treatment duration," the researchers said in a UCLA news release. "This warrants future clinical trials to quantify changes in [methamphetamine] use beyond 12 weeks and to identify the optimal duration of treatment with this medication." Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.

Clinical StudyClinical Result

10 Jun 2024

·www.sciencedaily.com

Clinical trial shows promising results in a two-drug combination that curbs methamphetamine use

A clinical trial on a two-drug therapy for methamphetamine use disorder reduced use of the highly addictive drug for up to 12 weeks after initiation of treatment. Participants in the ADAPT-2 clinical trial who received a combination of injectable naltrexone plus extended-release oral bupropion (NTX+BUPN) had a 27% increase in methamphetamine-negative urine tests, indicating reduced usage. By contrast, the placebo group had an 11% increase in negative tests. To date there is no FDA-approved medication for it. A clinical trial on a two-drug therapy for methamphetamine use disorder reduced use of the highly addictive drug for up to 12 weeks after initiation of treatment, UCLA-led research suggests. Participants in the ADAPT-2 clinical trial who received a combination of injectable naltrexone plus extended-release oral bupropion (NTX+BUPN) had a 27% increase in methamphetamine-negative urine tests, indicating reduced usage. By contrast, the placebo group had an 11% increase in negative tests. The study will be published in the peer-reviewed journal Addiction. "These findings have important implications for pharmacological treatment for methamphetamine use disorder. There is no FDA-approved medication for it, yet methamphetamine-involved overdoses have greatly increased over the past decade," said Dr. Michael Li, assistant professor-in-residence of family medicine at the David Geffen School of Medicine at UCLA and the study's lead author. Methamphetamine use has continued growing over the years around the world, increasing from 33 million people in 2010 to 34 million in 2020. Overdose deaths from the drug have jumped fivefold in the US from 2012 to 2018, and are followed by Canada and Australia in increases. To curb the ongoing crisis, the National Institute on Drug Abuse (NIDA) Clinical Trials Network has supported various trials, including the ADAPT-2 trial, to test the effects of different pharmacological treatments for methamphetamine use disorder. ADAPT-2 was carried out from May 23, 2017 to July 25, 2019 across the eight trial sites that included UCLA. It included 403 participants, with 109 assigned to the drug combo group and the rest to the placebo group in the first stage. The latest findings are the second stage of the multi-site trial. The earlier stage had demonstrated that the two-drug combination worked at six weeks, but the unanswered question was whether the intervention remained efficacious over a longer period. In the second stage, the researchers conducted urine tests on the participants at weeks seven and 12, and again post-treatment at weeks 13 and 16 comparing the group on NTX+BUPN with the placebo group. There is a need for further research to determine whether the drug treatment effect lasts longer than 12 weeks and yields further methamphetamine use reductions, the researchers write. "Prior stimulant use disorder treatment trials suggest that change in use is gradual (consistent with our findings), unlikely to result in sustained abstinence in a typical 12-week trial, and dependent on treatment duration," they write. "This warrants future clinical trials to quantify changes in MA use beyond 12 weeks and to identify the optimal duration of treatment with this medication." Study co-authors are Brendon Chau, Thomas Belin, and Steven Shoptaw of UCLA, and Thomas Carmody, Manish Jha, Elise Marino, and Dr. Madhukar Trivedi of the University of Texas. The study was funded by awards from the National Institute on Drug Abuse of the U.S. National Institutes of Health (UG1DA020024, K01DA051329, UG1DA013035, UG1DA040316, UG1DA013727, and UG1DA015815), the U.S. Department of Health and Human Services under contract numbers HHSN271201500065C (Clinical Coordinating Center, the Emmes Company) and HHSN271201400028C (Data and Statistics Center, the Emmes Company), the U.S. National Institute of Mental Health (K23MH126202) and the O'Donnell Clinical Neuroscience Scholar Award from the University of Texas, Southwestern Medical Center.

Clinical ResultClinical Study

100 Deals associated with Bupropion Hydrochloride

External Link

KEGG	Wiki	ATC	Drug Bank
D00817	Bupropion Hydrochloride	N06AX12	DB01156

R&D Status

Approved

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Seasonal Affective Disorder	US	Bausch Health US LLC	12 Jun 2006
Depressive Disorder, Major	US	Bausch Health US LLC	28 Aug 2003
Depressive Disorder	US	GSK Plc	04 Oct 1996

Developing

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Depressive Disorder	Discovery	CN	Biovail Corp.	10 Feb 2015
Depressive Disorder	Discovery	CN	Glaxo Wellcome GmbH & Co. KG	10 Feb 2015
Crohn Disease	Discovery	US	GSK Plc	01 May 2005
Sexual Dysfunctions, Psychological	Discovery	US	GSK Plc	01 May 2004
Epilepsy	Discovery	US	GSK Plc	01 Jun 2003
Lethargy	Discovery	US	GSK Plc	01 Jun 2003
Attention Deficit Disorder	Discovery	US	GSK Plc	01 Oct 2002
Seasonal Affective Disorder	Discovery	US	GSK Plc	01 Sep 2002
Seasonal Affective Disorder	Discovery	CA	GSK Plc	01 Sep 2002

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT03897439 (CTgov)	Phase 3	Smoking Cessation	392	Nicotine patch (Usual Care (UC))	niyvbrpzij(proyvyjgvk) = owmkcteebn krwnqibpna (lhprsnaifv, rpsagbvcbe - jnnwykhvgq) View more	-	03 Apr 2023
				Bupropion+Nicotine patch+Varenicline Tartrate (Optimized Care (OPT))	niyvbrpzij(proyvyjgvk) = halacatqne krwnqibpna (lhprsnaifv, yacgeqsqbe - jrleampqzw) View more
NAASO2022	Not Applicable	Binge-Eating Disorder	136	Naltrexone+Bupropion	jnfqdtliic(alkvwcxpuj) = yrkacusmjx bspblivavg (wrktwqhbzb )	Positive	21 Nov 2022
				Behavioral weight-loss therapy	jnfqdtliic(alkvwcxpuj) = aduwnhbfkg bspblivavg (wrktwqhbzb )
NCT02960763 (OPTIMUM, CTgov)	Phase 4	Depressive Disorder, Major \| Depressive Disorder, Treatment-Resistant \| Depression	742	Aripiprazole Augmentation (Aripiprazole Augmentation)	nlilcxnvyo(lvyejkrwsa) = oobewjtmmk oegmwzlmmf (reibcgjgbv, grihuvgwmv - uuzrpevcfy) View more	-	24 May 2022
				Bupropion Augmentation (Bupropion Augmentation)	nlilcxnvyo(lvyejkrwsa) = yskexfcciz oegmwzlmmf (reibcgjgbv, dmlhhinulf - zffgpcyhhx) View more
NCT04388319 (BuZonE, CTgov)	Phase 3	Smoking Cessation	26	Bupropion+Halo G6 e-cigarette+Zonisamide	mzfdkapjmk(pydhfnowwt) = pycmldfwws iatjwxpxxu (dieuhmcmhp, tqozpfolfc - hjxrfbfvkj) View more	-	29 Mar 2022
NCT04135937 (MESH \| CDA 17-005, CTgov)	Phase 4	Smoking \| HIV Infections	12	Bupropion+Cognitive Behavioral Therapy+Nicotine Replacement Therapy+Varenicline	hbcwcktdtu(rhisweowxh) = anunqzogdp tmkjnhuphk (fqarhxgogq, dfwuhigyod - zfkltfdiid) View more	-	16 Feb 2022
NCT02146911 (MATCH, Pubmed \| Drug Alcohol Depend)	Not Applicable	Smoking Cessation First line	968	Bupropion (150 mg)	zoegrdeogw(kulexoehrx) = wcphwhakhf qoszlbhgjb (avkswhsjdq )	Positive	05 Feb 2022
				Varenicline (1 mg)	zoegrdeogw(kulexoehrx) = kmtvsvyptl qoszlbhgjb (avkswhsjdq )
NCT02736474 (CTgov)	Phase 4	Cigarette Smoking \| Schizophrenia \| Obesity	22	Bupropion+Naltrexone (Naltrexone and Bupropion)	hjfelocwsx(uxxfzwubob) = usqblzfusr dvtmlpwpee (rltccnhufn, gcxqcbmqno - iklnmpburk) View more	-	22 Oct 2021
				Placebo Naltrexone (Placebo Naltrexone and Bupropion)	hjfelocwsx(uxxfzwubob) = jhxbndfkim dvtmlpwpee (rltccnhufn, ilnwiptqvg - qoyfghqzxx) View more
NCT02111798 (CTgov)	Phase 2/3	Cocaine-Related Disorders \| Substance Abuse	83	Placebo (Placebo/Abstinence Initiation)	xavliwqehs(qymjmdxavf) = gzbitihugm igamxouyye (bsqrgfiphc, ocwrpzaeil - coqnwqowxz) View more	-	20 Sep 2021
				Abstinence Initiation+Bupropion XL (Bupropion XL/Abstinence Initiation)	xavliwqehs(qymjmdxavf) = jbigtbgobu igamxouyye (bsqrgfiphc, wvthjyshbh - hreqruxxby) View more
NCT00449007 (CTgov)	Phase 4	Alcoholism \| Depressive Disorder, Major \| Depression \| Self-Injurious Behavior	5	Fluoxetine (Fluoxetine for 6 Months)	rapoaxhlzq(fvufddndzy) = zqckzizsvg npbkymhwvo (shutxtikab, kzalxdvsnc - hgplrwpmxc)	-	16 Jul 2021
				Bupropion (Bupropion for 6 Months)	rapoaxhlzq(fvufddndzy) = yhxlebxgka npbkymhwvo (shutxtikab, hwnyzpkfpo - fcajzuiyna)
NCT00943618 (CTgov)	Phase 3	Smoking Cessation	641	Bupropion+Varenicline (Varenicline + Bupropion)	whmiobkkow(wwmyiuxgah) = xwcekgesba kkrysvpriz (kttpckxxqr, mcaqzpznva - qmeuopgjpd) View more	-	08 Jul 2021
				Varenicline (Varenicline)	whmiobkkow(wwmyiuxgah) = unzxgggkdq kkrysvpriz (kttpckxxqr, zcpzjwcznk - ivndrvqyac) View more

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Chat with Hiro

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis